Promoted Content
Promoted Content

Find Dermatology Drugs in Phase II Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Botulinum toxin type A

            Therapeutic Area: Dermatology Product Name: ET-01

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Shanghai Haohai Biological Technology

            Deal Size: $40.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing March 09, 2021

            Details:

            One license is for Eirion's neuromodulator-based product candidates, ET-01 and AI-09 for aesthetic indications; and a second license is for Eirion's small molecule product candidates, ET-02 and ET-03, which are intended for the treatment of hair loss and hair greying.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Imsidolimab

            Therapeutic Area: Dermatology Product Name: ANB019

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 08, 2021

            Details:

            Imsidolimab treatment did not demonstrate statistically significant improvement over placebo in PPPASI change from baseline at week 16 primary endpoint.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DMT310

            Therapeutic Area: Dermatology Product Name: DMT310

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 21, 2021

            Details:

            DMT310 once weekly treatment reduced both inflammatory and noninflammatory lesions and had a greater proportion of IGA treatment success in patients with moderate-to-severe acne. DMT310 was well tolerated, with no clinically relevant differences in the incidence of AEs.